Facebook
Twitter
LinkedIn

Newsletter

Repositioning could lead to new funding
Facebook
Twitter
LinkedIn

BayBio is devoted to finding funding opportunities for our membership, including from foundations and NGOs.  As such, we’d like to highlight a program from The Michael J. Fox Foundation.

This past week The Michael J. Fox Foundation (MJFF) announced the launch of its Repositioning Drugs for PD 2012 program. The program follows a successful 2011 during which the Foundation funded nine awards totaling $3.4 million repositioning existing drugs that could benefit Parkinson’s disease patients.

The program seeks projects that will test drugs that are either already FDA-approved or that have been proven safe in a clinical trial for a certain indication, to determine whether the drug might be efficacious in the treatment of PD.  By identifying therapies that are already clinically available, MJFF hopes to reduce the time and cost it takes to bring potential drugs to market.  The studies can be pre-clinical or clinical in nature.

On October 18, interested applicants may participate in a conference call to find out more about this year’s program, at either 12:00 pm or 7:00 pm EST.  To participate, researchers must RSVP via email toconferencecalls@michaeljfox.org.  Participants will receive an email reply with further call-in details.    Pre-proposals will then be due by December 15.  Those interested should apply athttp://www.michaeljfox.org/research_openFundingPrograms_program.cfm?ID=51.